Biolinerx Stock Alpha and Beta Analysis
BLRX Stock | USD 0.32 0.23 41.82% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as BioLineRx. It also helps investors analyze the systematic and unsystematic risks associated with investing in BioLineRx over a specified time horizon. Remember, high BioLineRx's alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to BioLineRx's market risk premium analysis include:
Beta 0.0529 | Alpha (1.01) | Risk 6.77 | Sharpe Ratio (0.14) | Expected Return (0.98) |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
BioLineRx |
BioLineRx Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. BioLineRx market risk premium is the additional return an investor will receive from holding BioLineRx long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in BioLineRx. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate BioLineRx's performance over market.α | -1.01 | β | 0.05 |
BioLineRx expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of BioLineRx's Buy-and-hold return. Our buy-and-hold chart shows how BioLineRx performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.BioLineRx Market Price Analysis
Market price analysis indicators help investors to evaluate how BioLineRx stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading BioLineRx shares will generate the highest return on investment. By understating and applying BioLineRx stock market price indicators, traders can identify BioLineRx position entry and exit signals to maximize returns.
BioLineRx Return and Market Media
The median price of BioLineRx for the period between Sat, Aug 24, 2024 and Fri, Nov 22, 2024 is 0.51 with a coefficient of variation of 19.24. The daily time series for the period is distributed with a sample standard deviation of 0.1, arithmetic mean of 0.54, and mean deviation of 0.09. The Stock received substential amount of media coverage during this period. Price Growth (%) |
Timeline |
1 | BioLineRx initiated with a Buy at JonesResearch - TipRanks | 09/03/2024 |
2 | BioLineRx Now Covered by StockNews.com | 10/17/2024 |
3 | What is HC Wainwrights Estimate for BioLineRx Q3 Earnings | 11/08/2024 |
4 | BioLineRx stock hits 52-week low at 0.38 amid market challenges - Investing.com | 11/21/2024 |
About BioLineRx Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including BioLineRx or other stocks. Alpha measures the amount that position in BioLineRx has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
2023 | 2024 (projected) | Days Sales Outstanding | 24.5 | 21.78 | PTB Ratio | 7.88 | 8.27 |
BioLineRx Upcoming Company Events
As portrayed in its financial statements, the presentation of BioLineRx's financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, BioLineRx's leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of BioLineRx's public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of BioLineRx. Please utilize our Beneish M Score to check the likelihood of BioLineRx's management manipulating its earnings.
27th of March 2024 Upcoming Quarterly Report | View | |
22nd of May 2024 Next Financial Report | View | |
31st of December 2023 Next Fiscal Quarter End | View | |
27th of March 2024 Next Fiscal Year End | View | |
30th of September 2023 Last Quarter Report | View | |
31st of December 2022 Last Financial Announcement | View |
Build Portfolio with BioLineRx
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Additional Tools for BioLineRx Stock Analysis
When running BioLineRx's price analysis, check to measure BioLineRx's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioLineRx is operating at the current time. Most of BioLineRx's value examination focuses on studying past and present price action to predict the probability of BioLineRx's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioLineRx's price. Additionally, you may evaluate how the addition of BioLineRx to your portfolios can decrease your overall portfolio volatility.